elbion AG Completes EUR 25 Million Series A Financing
New Members of the Supervisory Board - In addition to the founding members Stephen Evans-Freke, Hartmut Michel and Otto Stolberg-Stolberg, three individuals were appointed to elbion's Supervisory Board, including (Chair) Ann F. Hanham, Ph.D., Managing Director, Burrill & Company; Klaus Stoeckemann, Ph.D., MBA, Director, 3i and Thomas Taapken, Ph.D., Partner, DVC. The Management Board includes Bernd Kastler (CEO) and Thomas Kronbach, Ph.D. (CSO).
Founded in 2002 as a management buy-out from Degussa's pharmaceutical group, elbion discovers and develops small molecules against inflammatory and CNS diseases. The company has a pipeline of products in different phases of development.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.